论文部分内容阅读
检测了卵巢恶性肿瘤患者血清及腹腔液总唾液酸（ＴＳＡ）和脂质结合唾液酸（ＬＳＡ）含量，并与正常女性及卵巢良性肿瘤患者比较。结果表明：卵巢恶性肿瘤患者血清及腹腔液ＴＳＡ、ＬＳＡ含量明显高于良性肿瘤及健康对照者（Ｐ＜０．０１，Ｐ＜０．００１），且血清及腹腔液ＴＳＡ、ＬＳＡ含量随卵巢恶性肿瘤临床分期的加重而升高（Ｐ＜０．０５，Ｐ＜０．０１）。提示血清及腹腔液ＴＳＡ、ＬＳＡ含量的测定可用于卵巢良、恶性肿瘤的鉴别及早期卵巢恶性肿瘤的诊断，并有助于了解卵巢恶性肿瘤患者术后病情变化，估计预后，观察疗效以指导临床治疗方案的及时更改。
Serum and peritoneal fluid total sialic acid (TSA) and lipid-bound sialic acid (LSA) levels were detected in patients with ovarian cancer and compared with normal women and benign ovarian tumors. The results showed that the contents of TSA and LSA in serum and peritoneal fluid of ovarian cancer patients were significantly higher than those of benign tumors and healthy controls (P <0.01, P <0.001). The levels of TSA and LSA in serum and peritoneal fluid were significantly correlated with ovarian malignancy The clinical stage of the tumor was aggravated and increased (P <0.05, P <0.01). It suggested that the determination of serum and peritoneal fluid TSA, LSA levels can be used for the diagnosis of ovarian benign and malignant tumors and early ovarian cancer, and help to understand the changes of postoperative patients with ovarian cancer, prognosis, observe the efficacy to guide the clinical Timely change of treatment plan.